{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-23-026258","form_type":"8-K","ticker":"DYAI","cik":"0001213809","company_name":"DYADIC INTERNATIONAL INC","filed_at":"2023-09-19T23:59:59+00:00","discovered_at":"2026-05-14T18:03:33.346087+00:00","generated_at":"2026-06-10T13:04:26.391275+00:00","sec_items":["1.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Dyadic signs exclusive license deal with INZYMES for dairy enzymes; $0.6M upfront","bullets":["Dyadic receives $0.6M upfront for development and licensing of Dapibus platform to INZYMES.","Exclusive license targets non-animal dairy enzymes used in food production.","Potential success fees, milestones, and royalties beyond upfront payment.","Addressable alternative protein market cited at >$60B, growing to $190B by 2028.","Deal builds on previous success producing animal-free casein proteins."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-23-026258","json":"https://secwatch.observer/filing/0001437749-23-026258.json","markdown":"https://secwatch.observer/filing/0001437749-23-026258.md","text":"https://secwatch.observer/filing/0001437749-23-026258.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1213809/000143774923026258/0001437749-23-026258-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1213809/000143774923026258/dyai20230918_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-10T13:04:26.391275+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"5f74dcfe2006890e9d4b097ee54443286aa8e07e","claim":"DYADIC INTERNATIONAL INC entered into Development and Exclusive License Agreement with INZYMES ApS valued at upfront payment of $0.6 million (effective 2023-09-18).","evidence_excerpt":"On September 18, 2023, Dyadic International (USA), Inc., a subsidiary of Dyadic International, Inc. (“Dyadic” or the “Company”) signed a Development and Exclusive License Agreement (the “Agreement”) with INZYMES ApS (“INZYMES”), a Denmark corporation, to develop and commercialize certain non-animal dairy enzymes used in the production of food products using Dyadic’s proprietary DapibusTM platform.","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1213809/000143774923026258/0001437749-23-026258-index.htm","confidence":0.95,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"license"},{"label":"Counterparty","value":"INZYMES ApS"},{"label":"Value","value":"upfront payment of $0.6 million"},{"label":"Effective","value":"2023-09-18"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}